A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

Completed · Phase 4 · Has a placebo group

Conditions studied: Parkinson Disease

In brief

Primary objective: to assess the efficacy of pramipexole given two times daily compared to placebo. Secondary objectives: to assess the effects of pramipexole on mood, cognition, fatigue, impulse control, daytime sleepiness and nighttime sleep compared to placebo; to compare the tolerability among the treatment groups over 12 weeks

Key facts

Study ID

NCT00402233

Run by

Boehringer Ingelheim

People needed

312

Starts

2006-11-01

Last updated by the study team

2014-05-16

Who can join

Age: 31 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Potential subjects must meet all of the following inclusion criteria to be eligible for enrollment into this study:
• Must be willing and able to give informed consent.
• Must be over 30 years of age at Baseline.
• Must have idiopathic Parkinson's disease of less than 7 years duration since diagnosis, characterized by 2 of the following 3 cardinal signs (signs need to be asymmetric): resting tremor, bradykinesia and rigidity.
• Must have a Modified Hoehn and Yahr stage <3.
• Should be able to safely tolerate placebo for up to 12 weeks after Baseline.
• Must have a negative urine pregnancy test at the Screening Visit and use an adequate contraceptive method throughout the study if a woman of child-bearing potential. Women who are surgically sterile (hysterectomy or tubal ligation) or whose last menstruation was 12 months or more prior to the Screening Visit are considered to be of non-child-bearing potential. Acceptable forms of contraception include oral, implanted, or injected contraceptives intrauterine devices in place for at least 3 months estrogen patch and adequate barrier methods in conjunction with spermicide. Abstinence is considered an acceptable contraceptive regimen.
• Must be willing and able to comply with trial procedures. They must be sufficiently proficient in English to understand and complete study instruments.

You may not qualify if…

• Individuals with any of the following characteristics will not be eligible for entry into this study:
• Signs or symptoms suggesting other parkinsonian syndromes.
• Use of medications that may cause secondary parkinsonism, including but not limited to: neuroleptics, metaclopramide, alphamethyldopa, flunarizine, methylphenidate, cinnarizine, reserpine, or amphetamines in the last 6 months prior to Baseline Visit.
• Use of dopaminergic medications within the last 3 months or for longer than 6 months prior to Baseline Visit.
• Presence of dementia by Diagnostic and Statistical Manual of Mental Disorders IV criteria (R06-1340) or a Mini Mental State Examination (R96-2656) (Appendix 10.1) score less than 26 at Screening Visit.
• Presence of major depression, as determined by medical history.
• Active epilepsy (i.e., occurrence of a seizure) within the past year prior to Baseline Visit.
• Electro Convulsive Therapy in previous 90 days prior to Baseline Visit.
• Myocardial infarction within previous 6 months prior to Baseline Visit.
• Third degree atrioventricular block or sick sinus syndrome.
• Congestive heart failure Class III or IV by New York Heart Association classification.
• Symptomatic orthostatic hypotension at Screening Visit.
• Stereotaxic brain surgery.
• Clinically significant liver disease.
• Clinically significant renal disease.
• Any other clinically significant medical or psychiatric condition (e.g., angina, active neoplasm) that in the judgment of the investigator would interfere with the subjects ability to participate in the study or would jeopardize safe conduct of the study.
• Breastfeeding.
• Known hypersensitivity or intolerability to pramipexole.
• Participating in other drug studies or receiving other experimental medications within 30 days of Baseline Visit.
• History of drug or alcohol dependency within 6 months of baseline visit.

Where it is running

• 248.622.170 Boehringer Ingelheim Investigational Site — Phoenix, Arizona, United States
• 248.622.112 Boehringer Ingelheim Investigational Site — Little Rock, Arkansas, United States
• 248.622.69 Boehringer Ingelheim Investigational Site — Fountain Valley, California, United States
• 248.622.198 Boehringer Ingelheim Investigational Site — La Jolla, California, United States
• 248.622.111 Boehringer Ingelheim Investigational Site — Oxnard, California, United States
• 248.622.61 Boehringer Ingelheim Investigational Site — Sacramento, California, United States
• 248.622.23 Boehringer Ingelheim Investigational Site — San Diego, California, United States
• 248.622.73 Boehringer Ingelheim Investigational Site — San Francisco, California, United States
• 248.622.108 Boehringer Ingelheim Investigational Site — Denver, Colorado, United States
• 248.622.190 Boehringer Ingelheim Investigational Site — Danbury, Connecticut, United States
• 248.622.215 Boehringer Ingelheim Investigational Site — Manchester, Connecticut, United States
• 248.622.196 Boehringer Ingelheim Investigational Site — Boca Raton, Florida, United States
• 248.622.14 Boehringer Ingelheim Investigational Site — Miami, Florida, United States
• 248.622.149 Boehringer Ingelheim Investigational Site — Weston, Florida, United States
• 248.622.139 Boehringer Ingelheim Investigational Site — Honolulu, Hawaii, United States
• 248.622.5 Boehringer Ingelheim Investigational Site — Chicago, Illinois, United States
• 248.622.138 Boehringer Ingelheim Investigational Site — Springfield, Illinois, United States
• 248.622.87 Boehringer Ingelheim Investigational Site — Louisville, Kentucky, United States
• 248.622.207 Boehringer Ingelheim Investigational Site — New Orleans, Louisiana, United States
• 248.622.132 Boehringer Ingelheim Investigational Site — Shreveport, Louisiana, United States
• 248.622.17 Boehringer Ingelheim Investigational Site — Boston, Massachusetts, United States
• 248.622.40 Boehringer Ingelheim Investigational Site — Boston, Massachusetts, United States
• 248.622.76 Boehringer Ingelheim Investigational Site — Boston, Massachusetts, United States
• 248.622.186 Boehringer Ingelheim Investigational Site — East Lansing, Michigan, United States
• 248.622.77 Boehringer Ingelheim Investigational Site — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.